LncRNA ITGB2-AS1 Could Promote the Migration and Invasion of Breast Cancer Cells through Up-Regulating ITGB2

Liu, Mengyao; Gou, Liyao; Xia, Jing; Wan, Qun; Jiang, Yi; Sun, Shilei; Tang, Min; He, Tong‐Chuan; Zhang, Yan

doi:10.3390/ijms19071866

Cited by 65 publications

(37 citation statements)

References 32 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, ITGB1 is essential for cancer chemo-resistance and metastasis mediated by aberrant actin-bundling protein in breast cancer stem cells [52], and its signaling foster resistance to inhibitors of HER2 and PI3K in HER2+ breast cancer [53,54]. Upregulation of ITGB2 promotes the migration and invasion in breast cancer [55].…”

Section: Discussionmentioning

confidence: 99%

Modeling and analysis of Hi-C data by HiSIF identifies characteristic promoter-distal loops

Zhou¹,

Cheng

Yang

et al. 2020

Genome Med

View full text Add to dashboard Cite

Current computational methods on Hi-C analysis focused on identifying Mb-size domains often failed to unveil the underlying functional and mechanistic relationship of chromatin structure and gene regulation. We developed a novel computational method HiSIF to identify genome-wide interacting loci. We illustrated HiSIF outperformed other tools for identifying chromatin loops. We applied it to Hi-C data in breast cancer cells and identified 21 genes with gained loops showing worse relapse-free survival in endocrine-treated patients, suggesting the genes with enhanced loops can be used for prognostic signatures for measuring the outcome of the endocrine treatment. HiSIF is available at https://github.com/yufanzhouonline/HiSIF.

show abstract

Section: Discussionmentioning

confidence: 99%

Modeling and analysis of Hi-C data by HiSIF identifies characteristic promoter-distal loops

Zhou¹,

Cheng

Yang

et al. 2020

Genome Med

View full text Add to dashboard Cite

show abstract

“…13b, R = 0.66, P < 2.2E − 16). ITGB2-AS1 has been shown to promote migration and invasion in cancer 34 , and is known to be involved in the regulation of T-cell and B-cell activation 35 . Moreover, we identified the lncRNAs that were correlated with immune cells by CIBERSORT 36 .…”

Section: Identification Of Immune-related Lncrnas Across Cancer Typesmentioning

confidence: 99%

Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers

et al. 2020

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are emerging as critical regulators of gene expression and they play fundamental roles in immune regulation. Here we introduce an integrated algorithm, ImmLnc, for identifying lncRNA regulators of immune-related pathways. We comprehensively chart the landscape of lncRNA regulation in the immunome across 33 cancer types and show that cancers with similar tissue origin are likely to share lncRNA immune regulators. Moreover, the immune-related lncRNAs are likely to show expression perturbation in cancer and are significantly correlated with immune cell infiltration. ImmLnc can help prioritize cancer-related lncRNAs and further identify three molecular subtypes (proliferative, intermediate, and immunological) of non-small cell lung cancer. These subtypes are characterized by differences in mutation burden, immune cell infiltration, expression of immunomodulatory genes, response to chemotherapy, and prognosis. In summary, the ImmLnc pipeline and the resulting data serve as a valuable resource for understanding lncRNA function and to advance identification of immunotherapy targets.

show abstract

“…High expression of MEG3 has been observed in APL patients and regulated miRNA expression in APL 12 . Furthermore, we also found some lncRNAs known to be involved in many types of solid tumors but without clear roles defined in APL, such as CRNDE [13][14][15][16] and ITGB2-AS1 17 .…”

Section: Identification Of Pathogenesis-related Lncrnas In Aplmentioning

confidence: 77%

Oncogenic role of lncRNA CRNDE in acute promyelocytic leukemia and NPM1-mutant acute myeloid leukemia

Zhang

Zhao

et al. 2020

Cell Death Discov.

View full text Add to dashboard Cite

The PML/RARα fusion protein acts in concert with cooperative genetic events in the development of acute promyelocytic leukemia (APL). However, oncogenic long non-coding RNAs (lncRNAs) cooperating with PML/RARα remain under-explored. Here, we first identified a set of pathogenesis-related lncRNAs, aberrantly expressed in APL using RNA-seq data from a large cohort of acute myeloid leukemia (AML) patients and normal counterparts. Among the pathogenesis-related lncRNAs, one of the evolutionarily conservative lncRNAs CRNDE (Colorectal Neoplasia Differentially Expressed) drew our attention. We found that CRNDE was highly expressed in the disease state but not in the preleukemic stage of APL, suggesting that CRNDE might be a secondary event coordinating with PML/RARα to promote APL development. Functional analysis showed that CRNDE knockdown induced differentiation and inhibited proliferation of APL cells, and prolonged survival of APL mice. Further mechanistic studies showed that CRNDE elicited its oncogenic effects through binding the miR-181 family and thereby regulating NOTCH2. Finally, we found that high CRNDE expression was also significantly correlated with NPM1 mutations and contributed to the differentiation block in NPM1-mutant AML. Collectively, our findings shed light on the importance of oncogenic lncRNAs in the development of AML and provide a promising target for AML therapy.

show abstract

LncRNA ITGB2-AS1 Could Promote the Migration and Invasion of Breast Cancer Cells through Up-Regulating ITGB2

Cited by 65 publications

References 32 publications

Modeling and analysis of Hi-C data by HiSIF identifies characteristic promoter-distal loops

Modeling and analysis of Hi-C data by HiSIF identifies characteristic promoter-distal loops

Pan-cancer characterization of immune-related lncRNAs identifies potential oncogenic biomarkers

Oncogenic role of lncRNA CRNDE in acute promyelocytic leukemia and NPM1-mutant acute myeloid leukemia

Contact Info

Product

Resources

About